Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria C Mir

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Nature Reviews. Urology|May 13, 2022
Complementary roles of surgery and systemic treatment in clear cell renal cell carcinomaAlexandre Ingels, Riccardo Campi, Umberto Capitanio, et al.
European Urology|February 1, 2022
Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysisZhenjie Wu, Qi Chen, Le Qu, et al.
European Urology|September 20, 2020
Surgical Management and Outcomes of Renal Tumors Arising from Horseshoe Kidneys: Results from an International Multicenter CollaborationEduard Roussel, Giovanni Tasso, Riccardo Campi, et al.
Oncotarget|January 18, 2015
CD117⁺ cells in the circulation are predictive of advanced prostate cancerBethany A Kerr, Ranko Miocinovic, Armine K Smith, et al.
Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology|August 1, 2020
Triggers for delayed intervention in patients with small renal masses undergoing active surveillance: a systematic reviewRiccardo Campi, Francesco Sessa, Francesco Corti, et al.
European Urology Open Science|April 4, 2024
Does the Timing of Cytoreductive Nephrectomy Impact Outcomes? Analysis of REMARCC Registry Data for Patients Receiving Tyrosine Kinase Inhibitor Versus Immune Checkpoint Inhibitor TherapyMargaret F Meagher, Andrea Minervini, Maria C Mir, et al.
Minerva Urology and Nephrology|October 29, 2021
Impact of frailty on perioperative and oncologic outcomes in patients undergoing surgery or ablation for renal cancer: a systematic reviewRiccardo Campi, Alessandro Berni, Daniele Amparore, et al.
Clinical Genitourinary Cancer|May 18, 2022
Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC RegistryMargaret F Meagher, Maria C Mir, Riccardo Autorino, et al.
European Urology Oncology|May 17, 2020
Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell CarcinomaEduard Roussel, Riccardo Campi, Alessandro Larcher, et al.
Frontiers in Oncology|April 17, 2023
Proposal for a Two-Tier Re-classification of Stage IV/M1 domain of Renal Cell Carcinoma into M1 ("Oligometastatic") and M2 ("Polymetastatic") subdomains: Analysis of the Registry for Metastatic Renal Cell Carcinoma (REMARCC)Margaret F Meagher, Maria C Mir, Andrea Minervini, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Nature Reviews. Urology|May 13, 2022
Complementary roles of surgery and systemic treatment in clear cell renal cell carcinomaAlexandre Ingels, Riccardo Campi, Umberto Capitanio, et al.
European Urology|February 1, 2022
Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysisZhenjie Wu, Qi Chen, Le Qu, et al.
European Urology|September 20, 2020
Surgical Management and Outcomes of Renal Tumors Arising from Horseshoe Kidneys: Results from an International Multicenter CollaborationEduard Roussel, Giovanni Tasso, Riccardo Campi, et al.
Oncotarget|January 18, 2015
CD117⁺ cells in the circulation are predictive of advanced prostate cancerBethany A Kerr, Ranko Miocinovic, Armine K Smith, et al.
Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology|August 1, 2020
Triggers for delayed intervention in patients with small renal masses undergoing active surveillance: a systematic reviewRiccardo Campi, Francesco Sessa, Francesco Corti, et al.
European Urology Open Science|April 4, 2024
Does the Timing of Cytoreductive Nephrectomy Impact Outcomes? Analysis of REMARCC Registry Data for Patients Receiving Tyrosine Kinase Inhibitor Versus Immune Checkpoint Inhibitor TherapyMargaret F Meagher, Andrea Minervini, Maria C Mir, et al.
Minerva Urology and Nephrology|October 29, 2021
Impact of frailty on perioperative and oncologic outcomes in patients undergoing surgery or ablation for renal cancer: a systematic reviewRiccardo Campi, Alessandro Berni, Daniele Amparore, et al.
Clinical Genitourinary Cancer|May 18, 2022
Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC RegistryMargaret F Meagher, Maria C Mir, Riccardo Autorino, et al.
European Urology Oncology|May 17, 2020
Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell CarcinomaEduard Roussel, Riccardo Campi, Alessandro Larcher, et al.
Frontiers in Oncology|April 17, 2023
Proposal for a Two-Tier Re-classification of Stage IV/M1 domain of Renal Cell Carcinoma into M1 ("Oligometastatic") and M2 ("Polymetastatic") subdomains: Analysis of the Registry for Metastatic Renal Cell Carcinoma (REMARCC)Margaret F Meagher, Maria C Mir, Andrea Minervini, et al.
Pageof 6